InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.85
(
-1.46%
)
US TECH 100
19,400.80
(
-2.29%
)
Dow Jones
41,852.42
(
-0.69%
)
Brent Oil
72.59
(
-0.05%
)
Bitcoin
70,471.95
(
-2.58%
)
Post# of 253493
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

tony111

Send PM Follow Ignore
Followers 10
Posts 1064
Boards Moderated 0
Alias Born 11/24/2007

tony111

Re: biomaven0 post# 98261

Friday, 07/02/2010 4:20:04 PM

Friday, July 02, 2010 4:20:04 PM

Post# of 253493
Lorcaserin has minimal side effects. The drug was studied up to two year and enrolled the most patients compared to Qnexa and Contrave's one year studies. The cardiovascular effect and abuse potential of Lorcaserin was thoroughly studied. All the analysts agree Lorcaserin is approvable based on safety, but argues the poor efficacy cannot compete with Qnexa. If Qnexa gets a thumb down due to safety, Lorcaserin basically has the whole pie.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up